RMD

ResMed
D

RMD

Arincen97/100B
235.255
USD
-4.06
(-1.69%)
Market Closed
Last updated: · Delayed 15 min
Fair value294.55Plus-20%185Price 235.26478
Q2 FY2027 · Earnings report
EPS estimate 3.03Revenue estimate 1.46B
OverviewFinancialsForecastEarningsDividendsCompany

ResMed revenue 1993–2027

ResMed's revenue in Q1 FY2027, the three months to 30 September 2026, was 1.41B USD, up 5.9% on the same quarter a year before. ResMed's revenue over the last twelve months was 5.73B USD, up 9.0% on the twelve months before. In fiscal year 2026 it was 5.65B USD, up 9.9% on the year before.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 20265.73B+9.04%3.51B1.59B
FY202630 Jun 20265.65B+9.85%3.45B1.52B
FY202530 Jun 20255.15B+9.84%3.05B1.40B
FY202430 Jun 20244.69B+10.95%2.66B1.02B
FY202330 Jun 20234.22B+18.02%2.36B897.56M
FY202230 Jun 20223.58B+11.93%2.02B779.44M
FY202130 Jun 20213.20B+8.11%1.84B474.51M
FY202030 Jun 20202.96B+13.44%1.72B621.67M
FY201930 Jun 20192.61B+11.38%1.54B404.59M
FY201830 Jun 20182.34B+13.23%1.36B315.59M
FY201730 Jun 20172.07B+12.40%1.20B342.28M
FY201630 Jun 20161.84B+9.52%1.07B352.41M
FY201530 Jun 20151.68B+7.97%1.01B352.89M
FY201430 Jun 20141.55B+2.68%989.79M345.27M
FY201330 Jun 20131.51B+10.66%940.66M307.13M
FY201230 Jun 20121.37B+10.08%820.74M254.85M
FY201130 Jun 20111.24B+13.80%741.33M226.99M
FY201030 Jun 20101.09B+18.64%655.48M190.09M
FY200930 Jun 2009920.74M+10.22%553.80M146.45M
FY200830 Jun 2008835.40M+16.62%493.75M110.30M
FY200730 Jun 2007716.33M+18.01%384.49M66.30M
FY200630 Jun 2006607.00M+42.65%376.90M88.21M
FY200530 Jun 2005425.51M+25.39%274.86M64.79M
FY200430 Jun 2004339.34M+24.04%216.74M57.28M
FY200330 Jun 2003273.57M+34.05%173.09M45.73M
FY200230 Jun 2002204.08M+31.53%133.25M37.51M
FY200130 Jun 2001155.16M+34.20%104.78M11.63M
FY200030 Jun 2000115.62M+30.49%84.87M22.23M
FY199930 Jun 199988.60M+33.23%63.80M16.10M
FY199830 Jun 199866.50M+35.16%47.10M10.60M
FY199730 Jun 199749.20M+42.20%31.50M7.50M
FY199630 Jun 199634.60M+47.23%18.90M4.50M
FY199530 Jun 199523.50M+69.06%12.80M2.80M
FY199430 Jun 199413.90M+80.52%8.00M1.20M
FY199330 Jun 19937.70M—4.80M800.00K

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

ResMed revenue growth by segment

Q1 FY2027 against Q1 FY2026

Sleep And Respiratory1.26B
+7.7%
Residential Care Software155.01M
-6.7%

ResMed revenue by segment over time

Sleep And Respiratory Software As Service Flow Generators Mask Systems Motors And Other Accessories Devices Devices And Masks
Fiscal yearSleep And RespiratorySoftware As ServiceFlow GeneratorsMask Systems Motors And Other AccessoriesDevicesDevices And Masks
FY20244.10B +10.1%584.13M +17.3%— — — —
FY20233.73B +17.2%497.98M +24.2%— — — —
FY20223.18B +12.5%400.83M +7.3%— — — —
FY20212.82B 373.59M +5.3%— — — —
FY2020— 354.63M +28.6%— — — 2.60B +11.7%
FY2019— 275.80M — — — 2.33B
FY2018— — — 879.60M +14.6%1.30B +12.3%—
FY2017— — — 767.70M +3.0%1.16B —
FY2016— — 1.06B +9.0%745.60M +6.1%— —
FY2015— — 975.90M +15.3%703.00M -0.7%— —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about ResMed's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.